Data are still needed on the incidence of irAEs in patients with active vs. stable autoimmune disease and on the use of DMARDs (disease-modifying antirheumatic drugs)/steroids at the initiation of ICI therapy and per ICI used (anti-PD1, antiPDL1, anti-CTLA4). The gene discussed is CTLA4; the disease is autoimmune disease.